Nutrient-Stimulating Hormone-Based Therapies for Obesity.

Dong Wook Kim, Caroline M Apovian, Cagney Cristancho

Journal: Endocrinology and metabolism clinics of North America 2025;54(1):103-119

PMID: 39919868

Full Text on Elsevier Science View on PubMed

Abstract

Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a new class of highly efficacious medications called nutrient-stimulating hormone (NuSH) therapies has emerged. This article highlights the effectiveness of the FDA-approved NuSH-based therapies-liraglutide, semaglutide, and tirzepatide-in long-term weight management. Ongoing trials are exploring novel mechanisms of action to simultaneously target multiple receptors involved in appetite and energy regulation, promising further advancements and additional treatment options in the field of obesity management.

Address: Center for Weight Management and Wellness, Division of Endocrinology, Diabetes and Hypertension, Brigham & Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA. Electronic address: [email protected].; Center for Weight Management and Wellness, Division of Endocrinology, Diabetes and Hypertension, Brigham & Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA.

DOI: 10.1016/j.ecl.2024.10.006

Link outs

Free resources

Medical:

https://medlineplus.gov/obesity.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Obesity, Glucagon-Like Peptides, Anti-Obesity Agents, Liraglutide, Glucagon-Like Peptide 1